There’s a particular energy at the American Diabetes Association Scientific Sessions. You feel it the moment you walk into the first plenary: the sense that diabetes and cardiometabolic research is accelerating, that the field is shifting under our feet, and that we’re watching the future of metabolic medicine take shape in real time.
This year reinforced something I’ve believed for a long time — diabetes is no longer a single-metabolic disease, and the therapies emerging today demand a far more sophisticated early‑phase approach than ever before.
The Rise of Oral Incretins — A Turning Point
One of the most prominent themes at ADA was the evolution of oral incretin therapies. For years, oral semaglutide has been the benchmark, but it comes with a challenge: its bioavailability depends heavily on strict dosing behaviour. Patients must avoid food and other medications for a set period of 30 minutes before taking it, and while many begin with good intentions, real‑world routines often take over. A small deviation — a sip of coffee, a bite of breakfast — can dramatically reduce the drug’s effectiveness.
This is why the new generation of small‑molecule oral GLP‑1 receptor agonists is so exciting. These molecules behave more like traditional oral small chemical molecules predictable, stable, and far easier to integrate into daily life. They don’t require fasting windows, and their bioavailability is significantly higher and more consistent. From a patient‑adherence perspective, this is a major step forward.
At ADA, it was clear that these therapies are poised to reshape second‑line treatment decisions for type 2 diabetes.
ACHIEVE 2: A Study That Signals a Shift in Practice
The ACHIEVE‑2 Phase 3 study was a focal point of discussion — and for good reason. It demonstrated that the small‑molecule oral GLP‑1 agonist orforglipron delivered stronger metabolic outcomes than dapagliflozin, an SGLT2 inhibitor commonly used as a second‑line therapy.
The results showed superior glucose control, greater reductions in body weight, and improvements in lipid profiles. For patients without renal or cardiac impairment, this represents a compelling alternative to SGLT2 inhibitors.
SGLT2 inhibitors still hold an important place in treatment — particularly for patients with heart failure or renal disease, where their protective effects are well established. But for the broader population, reports from ADA made it clear that oral incretins may soon becomea strong alternative next step after metformin.
This is a meaningful shift in clinical practice, and one that will influence trial design and early‑phase development for years to come.
Diabetes Is a Multi‑System Disease — And Trials Must Reflect That
Another striking theme at ADA was the consistent emphasis on diabetes as a multi‑system condition. Modern therapies affect far more than glucose. They affect body weight, fat tissue biology, inflammation, blood pressure, lipids, and the overall cardio-renal risk profile.
This means modern trials must measure far more than glucose as well.
The ACHIEVE‑2 study is a good example. Even though it wasn’t a cardiovascular outcomes trial, it still incorporated a broad set of metabolic endpoints — reflecting the reality that diabetes therapies exert effects across multiple organ systems.
For early‑phase development, this complexity is especially important. Sponsors need early signals across systems, not just one. They need to understand how a drug behaves in the body long before Phase 3. And they need partners who can design and perform studies that capture these signals with precision and scientific depth.
What ADA Means for Early‑Phase Development
If ADA made anything clear, it’s this: the future of cardiometabolic drug development will be defined by complexity — and by the need for early mechanistic clarity.
Sponsors will increasingly require:
- multi‑system endpoints
- sophisticated biomarker packages
- cardiac safety oversight
- metabolic profiling
- early‑phase study designs that anticipate downstream regulatory expectations
This is precisely the environment hVIVO’s early‑phase engine is built for. Our teams work across cardiometabolic, infectious disease, immunology, and respiratory therapeutics, and we’ve seen firsthand how modern mechanisms behave across systems. We understand how to design early‑phase studies that capture the right signals, at the right time, with the right depth.
ADA didn’t just validate the science. It validated the need for early‑phase partners who can keep pace with it.
Closing Thought
Leaving ADA this year, the message was unmistakable: diabetes research is accelerating, mechanisms are becoming more sophisticated, and early‑phase development is more important than ever.
For sponsors navigating this landscape, the right early‑phase partner isn’t just helpful — it’s essential.
And at hVIVO, we’re ready for what comes next.